Skip to main content
Caplight Logo









Invitrocue

Invitrocue

Private
SingaporeHealthcare & Life Scienceshttps://www.invitrocue.com/

Last Round

Convertible Debt

Dec 6, 2019

Total Funding Raised

$750,000

Company Overview

Invitrocue is a biotechnology research company that provides bio-analytic solutions, including in-vitro cell-based testing technologies, 3D cell-based models, and image analytics for drug development and personalized oncology.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Drug Discovery, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

patient-derived organoids3D cell modelspersonalized oncologypreclinical drug testingOnco-PDOchemosensitivity testingcontract research organizationCROprecision oncologydrug discovery servicesin-vitro modelsin-vivo modelstoxicology testinghumanized mice platformdigital pathology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invitrocue Comparables

Compare Invitrocue with similar companies based on industry and business-model similarity.

Invitrocue comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xilis
85%
Kiyatec
84%
Tempus
71%

Invitrocue Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtDec 6, 2019
Convertible DebtOct 1, 2019
Reverse MergerJan 27, 2016

Key People

Founding team and executive leadership

Steven Fang

CEO, Founder Executive Director

Founding Team

Invitrocue Investors

Notable investors and investment history

Invitrocue investors
InvestorRounds
ChinaLink ESGtConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    Monthly visitors increased 93% MoM.

  • Nov 8, 2025

    Monthly visitors grew 307% MoM, reaching 2.9K.

Invitrocue Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Invitrocue Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Invitrocue's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range25
Year Founded2012
Last FundingDec 6, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?